Dyno Therapeutics deal with Roche has potential for $1.8 billion in revenue

▴ Dyno Therapeutics deal with Roche has potential for $1.8 billion in revenue
This new partnership represents Dyno’s largest collaboration to date and this will expand the frontier of gene therapies for the central nervous system and liver

US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics has signed a collaboration and license agreement with Roche to apply Dyno’s CapsidMa platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) diseases and liver-directed therapies for the portfolio of both Roche and its Spark Therapeutics subsidiary.

Dyno Therapeutics, which was spun out of the lab of Professor George Church of Harvard and formed in late 2018 with a $9 million financing co-led by Polaris Partners and CRV, emerged from stealth in May this year, when it also announced a deal with the other Swiss pharma giant, Novartis, as well as one with US biotech Sarepta Therapeutics, which combined may be worth around $2 billion.

Under the terms of the latest accord, Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy, while Roche and Spark Therapeutics will be responsible for conducting pre-clinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids.

“This new partnership represents Dyno’s largest collaboration to date, and we are excited to work with Roche and Spark Therapeutics to expand the frontier of gene therapies for the central nervous system and liver. The Dyno, Roche and Spark teams share a bold vision for gene therapy and believe that enhancing vectors that deliver these therapies is key to developing new treatments for patients in need,” stated Dyno’s chief executive and co-founder Eric Kelsic.

“We strongly believe in the potential of gene therapy and are excited to bring together experts from Roche, Spark and Dyno to develop next-generation gene therapies. Dyno’s innovative AI-powered approach to designing optimized AAV vectors will further complement and build on our progress in gene therapy. We look forward to leveraging Dyno’s technology to develop new, innovative treatments for patients across CNS and liver-directed therapies,” said James Sabry, head of Roche Pharma Partnering.

Tags : #DynoTherapeutics #LatestNewsonDynoTherapeutics15thOct #Roche #LatestNewsonRocheon15thct #LatestPharmaCollaboration15thOct #GeneTherapiesforCNSandLiver #EricKelsic #Novartis #GeorgeChurchofHarvard #JamesSabry

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026